CN109528720B - Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 - Google Patents
Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 Download PDFInfo
- Publication number
- CN109528720B CN109528720B CN201910016384.9A CN201910016384A CN109528720B CN 109528720 B CN109528720 B CN 109528720B CN 201910016384 A CN201910016384 A CN 201910016384A CN 109528720 B CN109528720 B CN 109528720B
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- mice
- tumor
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910912293.3A CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
CN201910016384.9A CN109528720B (zh) | 2019-01-08 | 2019-01-08 | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910016384.9A CN109528720B (zh) | 2019-01-08 | 2019-01-08 | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910912293.3A Division CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109528720A CN109528720A (zh) | 2019-03-29 |
CN109528720B true CN109528720B (zh) | 2021-03-30 |
Family
ID=65834373
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910016384.9A Active CN109528720B (zh) | 2019-01-08 | 2019-01-08 | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN201910912293.3A Active CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910912293.3A Active CN110624108B (zh) | 2019-01-08 | 2019-01-08 | Fas或其配体FasL作为靶点在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN109528720B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023088356A1 (zh) * | 2021-11-22 | 2023-05-25 | 宁波康柏睿格医药科技有限公司 | Rip2抑制剂联合化疗药物的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458841A (zh) * | 2000-07-17 | 2003-11-26 | 克里斯蒂安·西蒙 | 应用基质金属蛋白酶抑制剂治疗癌症 |
WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
WO2013169479A1 (en) * | 2012-05-11 | 2013-11-14 | Massachusetts Institute Of Technology | Compositions and methods of treatment of drug resistant cancers |
WO2017117182A1 (en) * | 2015-12-29 | 2017-07-06 | Board Of Regents, The University Of Texas System | Inhibition of p38 mapk for the treatment of cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002239578A1 (en) * | 2000-11-07 | 2002-05-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as repreesented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Enhanced efficacy and safety of genotoxic therapy by p38 mapk modulation |
-
2019
- 2019-01-08 CN CN201910016384.9A patent/CN109528720B/zh active Active
- 2019-01-08 CN CN201910912293.3A patent/CN110624108B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458841A (zh) * | 2000-07-17 | 2003-11-26 | 克里斯蒂安·西蒙 | 应用基质金属蛋白酶抑制剂治疗癌症 |
WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
WO2013169479A1 (en) * | 2012-05-11 | 2013-11-14 | Massachusetts Institute Of Technology | Compositions and methods of treatment of drug resistant cancers |
WO2017117182A1 (en) * | 2015-12-29 | 2017-07-06 | Board Of Regents, The University Of Texas System | Inhibition of p38 mapk for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
CN110624108B (zh) | 2022-04-05 |
CN110624108A (zh) | 2019-12-31 |
CN109528720A (zh) | 2019-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | STAT3 activation-induced fatty acid oxidation in CD8+ T effector cells is critical for obesity-promoted breast tumor growth | |
KR20160093012A (ko) | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 | |
WO2019083971A1 (en) | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | |
CN102223896A (zh) | 抗-β-2-微球蛋白试剂及其用途 | |
WO2012075291A1 (en) | Compositions and methods for treating foxp3+ treg related diseases | |
EP3915585A1 (en) | Therapeutic combinations comprising agonists of ferroptosis for treating proliferative disorders | |
Thompson et al. | FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female mice | |
JP2023053338A (ja) | Gvhd又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節 | |
US20110184045A1 (en) | Silencng and rig-i activation by dual function oligonucleotides | |
KR102377702B1 (ko) | Syt11 억제제를 유효성분으로 포함하는 위암 치료용 조성물 | |
CN109528720B (zh) | Sb203580在制备抗肿瘤药物中的应用及抗肿瘤药物 | |
US20170369841A1 (en) | Method for modifying t cell population | |
CN111166867B (zh) | Pd-1泛素化激动剂的功能与用途 | |
CN108888620B (zh) | 化合物knk437的新应用 | |
KR101384360B1 (ko) | Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 | |
US9752145B2 (en) | Compositions and methods for reducing C/EBP homologous protein activity in myeloid-derived suppressor cells | |
Yuan et al. | Targeting complement C5a to improve radiotherapy sensitivity in non-small cell lung cancer | |
CN107529558B (zh) | 多聚核苷酸-5’激酶-3’磷酸酶的新应用 | |
Le et al. | NF-κB-regulated VentX expression mediates tumoricidal effects of chemotherapeutics at noncytotoxic concentrations | |
WO2020073642A1 (zh) | 靛玉红类化合物和硼替佐米在制备治疗多发性骨髓瘤的药物中的用途 | |
CN108079301B (zh) | 减少cxcl13蛋白活性或表达量的活性物质在制备治疗恶性肿瘤转移药物中的用途 | |
CN106554962B (zh) | 过表达gpr160的癌症的预防、诊断和治疗 | |
WO2019136621A1 (en) | Nr4a1 as key mediator of t cell tolerance | |
CN108159419B (zh) | 诱导irf8表达的物质在制备治疗肝癌的药物中的应用 | |
CN108379584B (zh) | RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Cai Zhijian Inventor after: Wang Jianli Inventor after: Shen Yingying Inventor after: Song Zhengbo Inventor after: Ma Zeyu Inventor after: Zhang Bei Inventor after: Lu Chaojie Inventor before: Wang Jianli Inventor before: Cai Zhijian Inventor before: Shen Yingying Inventor before: Song Zhengbo Inventor before: Ma Zeyu Inventor before: Zhang Bei Inventor before: Lu Chaojie |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |